ライフサイエンスコーパス: corneal transplant

1 stantial mismatch between need and supply of corneal transplant.

2 Patients underwent corneal transplant.

3 lindness patients who are not eligible for a corneal transplant.

4 sess the rate of SARS-CoV-2 transmission via corneal transplant.

5 pecially in patients planned for or awaiting corneal transplant.

6 atients who had undergone a unilateral first corneal transplant.

7 ts concerning awareness and attitudes toward corneal transplant.

8 plenectomized patient receiving a (lamellar) corneal transplant.

9 llagen cross-linking, or, in advanced cases, corneal transplant.

10 l component in selecting tissue suitable for corneal transplant.

11 ue would seem to have clinical relevance for corneal transplant.

12 f surgical technique in the success rates of corneal transplants.

13 ion for patients ineligible for conventional corneal transplants.

14 een accidentally transmitted by contaminated corneal transplants.

15 measures were follow-up inquiries from 6592 corneal transplants.

16 asing success in patients who have undergone corneal transplants.

17 ved in generating the alloimmune response to corneal transplants.

18 osis in the failure of orthotopic allogeneic corneal transplants.

19 layed-type hypersensitivity and rejection of corneal transplants.

20 le hope of visual recovery from conventional corneal transplants.

21 or histocompatibility complex MHC-mismatched corneal transplants.

22 ments in the long-term survival of high-risk corneal transplants.

23 hown to participate in long-term survival of corneal transplants.

24 The indication for corneal transplant affects the risk for developing postk

25 e over time during the study period for both corneal transplant and cataract surgery procedures; howe

26 Such a test might enhance safety of corneal transplants and some other tissue-derived produc

27 ncluding keratoconus, corneal scarring, post-corneal transplant, and post-refractive surgery.

28 thways can significantly promote survival of corneal transplants, and suggest that select deletion or

29 As corneal transplants are met with high rejection rates in

30 ining lymph nodes of allogeneic or syngeneic corneal transplanted BALB/c mice.

31 the records of 8,378 patients who underwent corneal transplants between 2009 and 2022.

32 ation when they were recipients of syngeneic corneal transplants but also exhibited significantly inc

33 a major barrier to the success of allogeneic corneal transplants, but the specific mediators and mech

34 for keratoconus between 2003 and 2018 in all corneal transplant centers in the UK were compared to ad

35 mpared with the cataract surgery cohort, the corneal transplant cohort had a higher adjusted hazard r

36 ence rates ranged from 0.11% to 1.05% in the corneal transplant cohort, 0.06% to 0.20% in the catarac

37 e was a wider year-to-year variation for the corneal transplant cohort.

38 Acute rejection (AR) of corneal transplants (CT) has a profound effect on subseq

39 More corneal transplants, especially DALKs and endokeratoplas

40 nex and enzyme-linked immunosorbent assay on corneal transplant extracts at different times after sur

41 s that are associated with increased risk of corneal transplant failure, the extent to which these ri

42 rgeons enrolled 1090 participants undergoing corneal transplant for a moderate-risk condition, princi

43 ents were included who had undergone a first corneal transplant for keratoconus (KC), Fuchs endotheli

44 Nine patients underwent 15 corneal transplants for corneal clouding (14/15 procedur

45 rent recommendations are to avoid tissue for corneal transplant from donors with coronavirus disease

46 CB6F1 mice were grafted with orthotopic corneal transplants from C3H donors (mismatch at the ent

47 atibility, including H-Y incompatibility, on corneal transplant graft rejection and failure.

48 (95% confidence interval [CI] 2.4%-6.8%) of corneal transplants had failed within the follow-up peri

49 nts who could benefit from a sight-restoring corneal transplant have access to cadaveric donor cornea

50 Patients with corneal transplants have a high frequency of developing

51 rategies including NSAIDs, steroids, MMC and corneal transplants have shown tremendous success but wi

52 Allogeneic T cells from corneal transplant hosts promote VEC proliferation, prob

53 APC-dependent direct response is elicited in corneal transplant hosts when the graft bed is inflamed

54 f CCR1 can be a useful therapeutic target in corneal transplant immunity.

55 phy (FECD) is the most common indication for corneal transplant in the United States.

56 defense mechanism and may enable subsequent corneal transplant in these patients.

57 All corneal transplants in both the control and the topical

58 Second and subsequent corneal transplants in the same eye are more prone to re

59 The risk of COVID-19 infection via corneal transplant is low even in donors with SARS-CoV-2

60 In corneal-transplanted mice, the CD4+ T-cell response was

61 netrating globe injury or operation, such as corneal transplant or cataract extraction.

62 he trend of infectious endophthalmitis after corneal transplant or cataract surgery through examining

63 Patients undergoing corneal transplant or cataract surgery were identified u

64 lmitis at 6-week and 6-month intervals after corneal transplant or cataract surgery.

65 of center or surgeon transplant workload on corneal transplant outcome.

66 .5), or a previous history of multiple donor corneal transplants (P > .5).

67 The United States, with 199.10-6 corneal transplants per capita, had the highest transpla

68 if registering more than 50 and less than 10 corneal transplants per year, respectively; surgeons wer

69 In 2012, we identified 184,576 corneal transplants performed in 116 countries.

70 Almost half the corneal transplants performed in the United States are d

71 indications were Fuchs dystrophy (39% of all corneal transplants performed), a primary corneal edema

72 VEGF-C as a potentially important target in corneal transplant pharmacotherapy and immunobiology.

73 Administering MDSC to HR corneal transplant recipients demonstrates prolonged gra

74 s than either normal controls (P = 0.017) or corneal transplant recipients not undergoing graft rejec

75 e completion of recommended vaccinations for corneal transplant recipients, without significantly inc

76 imulatory pathway promotes the acceptance of corneal transplants, regardless of the degree of allodis

77 -year follow-up data reported to The Swedish Corneal Transplant Register were included, totaling 1677

78 om the prospective cohort from the Singapore Corneal Transplant Registry were included.

79 om our prospective cohort from the Singapore Corneal Transplant Registry.

80 ic to EMAP between patients at high risk for corneal transplant rejection and control subjects (P<0.0

81 The rates of corneal transplant rejection were similar among B-cell-d

82 upports allograft survival in vivo, prevents corneal transplant rejection, and attenuates the progres

83 cal lymphangiogenesis mediates diseases like corneal transplant rejection, dry eye disease, and aller

84 of Fas mRNA expression in blood during human corneal transplant rejection.

85 vels of Fas mRNA in blood may have a role in corneal transplant rejection.

86 Data on vaccine-associated corneal transplant rejections are limited.

87 s and below were included from the Singapore Corneal Transplant Study between April 4, 1991 and April

88 nter from the ongoing, prospective Singapore Corneal Transplant Study.

89 om our prospective cohort from the Singapore Corneal Transplant Study.

90 ngoing prospective cohort from the Singapore Corneal Transplant Study.

91 d from subjects in the prospective Singapore Corneal Transplant Study.

92 om our prospective cohort from the Singapore Corneal Transplant Study.

93 , Germany, tertiary hospital, performing 500 corneal transplant surgeries per year.

94 patients undergoing glaucoma, cataract, and corneal transplant surgeries.

95 The reasons for having combined glaucoma and corneal transplant surgery are myriad.

96 on of sVEGFR-3 leads to a 5-fold increase in corneal transplant survival in mouse models.

97 L-1 receptor antagonist (IL-1ra) can prolong corneal transplant survival in the murine model of ortho

98 Newer corneal transplant techniques may have a lower risk for

99 Recent advances in corneal transplant technology promise to repair the corn

100 4+ T cells and CD8+ T cells were examined in corneal transplants that expressed genetically defined m

101 In high-risk corneal transplants, the increase in En/DMT allowed pred

102 However, in a substantial proportion of corneal transplants, the rates of acute rejection and/or

103 ts with MPS I spectrum disease who underwent corneal transplant to treat corneal clouding between May

104 survival of both minor H- and MHC-disparate corneal transplants to 100% (P = 0.0001) and 92% (P = 0.

105 antigen-mismatched (BALB.b; n=62) orthotopic corneal transplants to determine the effect of selective

106 Next, we investigated whether failure of corneal transplants to induce a CD4+ direct alloresponse

107 For corneal transplants undertaken in the periods 1999-2002,

108 Corneal transplants were done in BALB/c mice from C57BL/

109 A total of 3486 corneal transplants were undertaken: 1973 for FED, 1513

110 mune privileged site is the success of human corneal transplants, where a very high percentage of tra

111 ion and corneal graft rejection in high-risk corneal transplants with antecedent rejection or neovasc

112 bling clinicians and researchers to generate corneal transplants with sufficiently high fractions of